Our groups
Jan Paul Medema Group

Experimental Oncology and Radiobiology

Amsterdam UMC
Kép

Our Focus

The laboratory of Experimental Oncology and Radiobiology houses multiple research teams under my supervision and the supervision of L. Vermeulen. These teams study cancers of the gastrointestinal tract, specifically oesophageal, pancreas and colorectal cancer. The aim is to understand the heterogeneity present within cancers and between distinct cancer patients. For pancreas and colorectal cancer, we have been instrumental in the design of molecular subtypes that identify patient groups with clearly distinctive tumours from a biological point of view. Understanding the way these molecular subtypes arise and how they are wired in molecular terms is key to our research program. In addition, we aim to reveal subtype -specific vulnerabilities in order to design better therapies. Interaction with the microenvironment, the ECM, nutrients, microvasculature and immune components is part of our studies to unravel the subtypes and to find novel targets for therapy.   

For our studies we depend on primary tumour material from patients and hence we have optimal connection to several clinical departments. Moreover, organoids and xenografts derived from human tumour as well as a wide range of mouse models is part of our research infrastructure.   

About Jan Paul Medema

Name

Jan Paul Medema

Position
Oncode Investigator at AMC
LinkedIn
View LinkedIn profile
Awards
  • 2009: Dutch Society of Gastroenterology Tytgat award
  • 2007: VICI laureate of the Dutch Science Organization
  • 2002: C.J.Kok prize
  • 2000: VIDI laureate of the Dutch Science Organization
  • 1996: Dutch Cancer Society Fellowship
  • Honorary Professorship Brunel University London, UK
Key publications
  1. Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L.,…..& Medema, J.P. (2022). BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Reports, 38(7):110374.
  2. Ramesh, P., Lannagan, T.R.M., Jackstadt, R,, Atencia Taboada, L., Lansu, N.,….& Medema, J.P. (2021) BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differentiation, 28(12):3282-3296.
  3. Linnekamp, J.F., Hooff, S.R.V., Prasetyanti, P.R., Kandimalla, R., Buikhuisen, J.Y.,…..& Medema JP. (2018)Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differentiation, 25(3):616-633.
  4. Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., …., Medema, J.P.* &….. Tejpar S.* (2015). The consensus molecular subtypes of colorectal cancer. Nature Medicine, 21(11):1350-6.
  5. Felipe De Sousa, E. M., Wang, X., Jansen, M., Fessler, E., Trinh, A., De Rooij, L. P., ... Medema J.P.* & Vermeulen, L.* (2013). Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine, 19(5), 614.
  6. Vermeulen, L., Felipe De Sousa, E. M., Van Der Heijden, M., Cameron, K., De Jong, J. H., Borovski, T., ... & Medema J.P. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12(5), 468.
  7. *shared senior authorships
Name

Jan Paul Medema

Position
Oncode Investigator at AMC
LinkedIn
View LinkedIn profile
Awards
  • 2009: Dutch Society of Gastroenterology Tytgat award
  • 2007: VICI laureate of the Dutch Science Organization
  • 2002: C.J.Kok prize
  • 2000: VIDI laureate of the Dutch Science Organization
  • 1996: Dutch Cancer Society Fellowship
  • Honorary Professorship Brunel University London, UK
Key publications
  1. Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L.,…..& Medema, J.P. (2022). BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Reports, 38(7):110374.
  2. Ramesh, P., Lannagan, T.R.M., Jackstadt, R,, Atencia Taboada, L., Lansu, N.,….& Medema, J.P. (2021) BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differentiation, 28(12):3282-3296.
  3. Linnekamp, J.F., Hooff, S.R.V., Prasetyanti, P.R., Kandimalla, R., Buikhuisen, J.Y.,…..& Medema JP. (2018)Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differentiation, 25(3):616-633.
  4. Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., …., Medema, J.P.* &….. Tejpar S.* (2015). The consensus molecular subtypes of colorectal cancer. Nature Medicine, 21(11):1350-6.
  5. Felipe De Sousa, E. M., Wang, X., Jansen, M., Fessler, E., Trinh, A., De Rooij, L. P., ... Medema J.P.* & Vermeulen, L.* (2013). Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine, 19(5), 614.
  6. Vermeulen, L., Felipe De Sousa, E. M., Van Der Heijden, M., Cameron, K., De Jong, J. H., Borovski, T., ... & Medema J.P. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12(5), 468.
  7. *shared senior authorships
Awards

  • 2009: Dutch Society of Gastroenterology Tytgat award

  • 2007: VICI laureate of the Dutch Science Organization

  • 2002: C.J.Kok prize

  • 2000: VIDI laureate of the Dutch Science Organization

  • 1996: Dutch Cancer Society Fellowship

  • Honorary Professorship Brunel University London, UK

Key Publications

  1. Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L.,…..& Medema, J.P. (2022). BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. Cell Reports, 38(7):110374.

  2. Ramesh, P., Lannagan, T.R.M., Jackstadt, R,, Atencia Taboada, L., Lansu, N.,….& Medema, J.P. (2021) BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differentiation, 28(12):3282-3296.

  3. Linnekamp, J.F., Hooff, S.R.V., Prasetyanti, P.R., Kandimalla, R., Buikhuisen, J.Y.,…..& Medema JP. (2018)Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differentiation, 25(3):616-633.

  4. Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., …., Medema, J.P.* &….. Tejpar S.* (2015). The consensus molecular subtypes of colorectal cancer. Nature Medicine, 21(11):1350-6.

  5. Felipe De Sousa, E. M., Wang, X., Jansen, M., Fessler, E., Trinh, A., De Rooij, L. P., ... Medema J.P.* & Vermeulen, L.* (2013). Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine, 19(5), 614.

  6. Vermeulen, L., Felipe De Sousa, E. M., Van Der Heijden, M., Cameron, K., De Jong, J. H., Borovski, T., ... & Medema J.P. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12(5), 468.

*shared senior authorships

Members

Jan Paul Medema
Oncode Investigator		Arezo Torang    
PhD student		Benthe H. Doeve    
PhD student
Ciro Longobardi    
PhD student		Joan de Jong     
Technician		Katherine Cameron     
Technician
Lidia Atencia Taboada    
PhD student		Martin Huisman    
Technician		Polina Deenichina    
Phd student
Rebecca Roessler    
Phd student		Roxan Helderman    
Postdoc		Saskia van den Bergh    
Technician
Selami Baglamis    
Technician		Tobias Ackermann    
PostDoc		Valérie Wouters    
PhD student
Ynze van Cleef    
Bioinformatician